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ABSTRACT
Objective Tofacitinib is an oral Janus kinase ( JAK)
inhibitor for the treatment of rheumatoid arthritis (RA).
The pathways affected by tofacitinib and the effects on
gene expression in situ are unknown. Therefore,
tofacitinib effects on synovial pathobiology were
investigated.
Methods A randomised, double-blind, phase II serial
synovial biopsy study (A3921073; NCT00976599) in
patients with RA with an inadequate methotrexate
response. Patients on background methotrexate received
tofacitinib 10 mg twice daily or placebo for 28 days.
Synovial biopsies were performed on Days -7 and 28
and analysed by immunoassay or quantitative PCR.
Clinical response was determined by disease activity
score and European League Against Rheumatism
(EULAR) response on Day 28 in A3921073, and at
Month 3 in a long-term extension study (A3921024;
NCT00413699).
Results Tofacitinib exposure led to EULAR moderate to
good responses (11/14 patients), while placebo was
ineffective (1/14 patients) on Day 28. Tofacitinib
treatment significantly reduced synovial mRNA expression
of matrix metalloproteinase (MMP)-1 and MMP-3
(p<0.05) and chemokines CCL2, CXCL10 and CXCL13
(p<0.05). No overall changes were observed in synovial
inflammation score or the presence of T cells, B cells or
macrophages. Changes in synovial phosphorylation of
signal transducer and activator of transcription 1 (STAT1)
and STAT3 strongly correlated with 4-month clinical
responses (p<0.002). Tofacitinib significantly decreased
plasma CXCL10 (p<0.005) at Day 28 compared with
placebo.
Conclusions Tofacitinib reduces metalloproteinase and
interferon-regulated gene expression in rheumatoid
synovium, and clinical improvement correlates with
reductions in STAT1 and STAT3 phosphorylation.
JAK1-mediated interferon and interleukin-6 signalling
likely play a key role in the synovial response.
Trial registration number NCT00976599.
INTRODUCTION
Cytokines play a critical role in the pathogenesis of
rheumatoid arthritis (RA).1–3 Targeted biologics
that block individual cytokines, such as tumour
necrosis factor (TNF) or interleukin (IL)-6, have
demonstrated clinical efficacy.4 Targeting intracellu-
lar pathways represents a novel approach of inhibit-
ing the effects of multiple cytokines.5 6
Signal transduction allows the cell to sense cyto-
kines in the external environment and initiate a cel-
lular response.5 7 8 One example is the Janus
kinase ( JAK) family, which integrates signals from
many cytokines.9 10 Four JAK proteins ( JAK1,
JAK2, JAK3 and tyrosine kinase 2 [Tyk2]) associate
with the intracellular domains of surface cytokine
receptors.9 10 Combinations of the JAK proteins
allow site and event specificity, including JAK1/
JAK3 for many T cell-derived cytokines, JAK1/
JAK2 for IL-6, and JAK1/Tyk2 for interferons
(IFNs).10 11 JAKs phosphorylate the signal transdu-
cers and activators of transcription (STATs) to
modulate gene expression.10 12
The JAK inhibitor tofacitinib has proven effective
in the treatment of RA.13–18 Tofacitinib is a targeted,
small molecule inhibitor of several JAK isoforms,
especially JAK3 and JAK1.19 We hypothesised that
tofacitinib targets cytokine signalling critical to the
pathogenesis of rheumatoid synovitis. Therefore, a
double-blind, placebo-controlled serial synovial
biopsy study was performed in patients with RAwith
an inadequate response to methotrexate. Treatment
with tofacitinib reduced expression of matrix metal-
loproteinase (MMP) and IFN-regulated genes in
rheumatoid synovium. Reduction of pSTAT1 and
pSTAT3 measured in synovial biopsies at Month 1
was highly correlated with clinical improvement at
Month 4. These data are consistent with tofacitinib
acting on synovial JAK/STAT targets and suggest that
JAK1-mediated signalling of IFNs and IL-6 plays a
role in the synovial response to JAK blockade.
METHODS
Study design and patients
A randomised, double-blind, placebo-controlled
phase II, 28-day clinical study was performed
across six centres in the USA (A3921073;
NCT00976599). Patients were randomised 1:1 to
tofacitinib 10 mg twice daily or placebo, all in com-
bination with methotrexate. Patients were aged
≥18 years with active RA based on the American
College of Rheumatology (ACR) 1987 Revised
Criteria.20 Active disease was defined as ≥4 tender/
painful and ≥4 swollen joints (of 68/66 joints
examined), and either an erythrocyte sedimentation
rate (ESR) >28 mm/h (Westergren method) or a C
reactive protein level >7 mg/L. Patients had to have
at least one knee, one elbow, one wrist or two
metacarpophalangeal joints with active synovitis
suitable for biopsy. Patients were receiving stable
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doses of 7.5–25 mg of methotrexate weekly and had an incom-
plete response.
Key exclusion criteria included: current treatment with other
disease-modifying antirheumatic agents, including biologics;
arthroscopy or intra-articular steroids within the previous
3 months; haemoglobin <9.0 mg/dL; absolute neutrophil count
<1.2×109/L; recent, current or chronic infection; evidence of
active, latent or inadequately treated Mycobacterium tubercu-
losis infection; or history of lymphoproliferative disorder or
malignancy.
Patients were randomised in a 1:1 design to receive tofacitinib
10 mg twice daily or matching placebo tablets with background
methotrexate. Approximately 4–10 days prior to the initiation
of study drug, and at about Day 28 of dosing, the patients had
arthroscopy under local anaesthesia or conscious sedation. The
arthroscopy was performed on a clinically inflamed knee/elbow/
wrist/metacarpophalangeal joint, selected by the investigator.
Patients from this study were eligible to enter an ongoing
open-label, long-term extension (LTE) study (A3921024;
NCT00413699; ongoing, 10 April 2013 data cut) 1 week after
the second biopsy. Patients were followed up for both efficacy
and safety within this LTE study and the results correlated with
the Month 1 biopsy data for tofacitinib-treated patients.
This study was performed in compliance with the Declaration
of Helsinki and Good Clinical Practice Guidelines established
by the International Conference on Harmonisation. The final
protocol, amendments and informed consent documentation
were reviewed and approved by the institutional review board
and the independent ethics committee of each investigational
centre. All patients provided written informed consent.
Endpoints
The primary objective was to evaluate the effect of tofacitinib
10 mg twice daily on synovial tissue and blood biomarkers in
active RA compared with placebo at Day 28. Secondary objec-
tives were to evaluate the clinical efficacy, safety and tolerability
of tofacitinib. The primary clinical outcomes were the disease
activity score (DAS) based on a 28-joint count (DAS28-4 [ESR])
and the percentage of patients at Day 28 who met the criteria
for an ACR20, ACR50 or ACR70 response (≥20%, ≥50% and
≥70% reduction of the composite ACR measures).2 Safety end-
points included the incidence and severity of adverse events and
clinical laboratory abnormalities. DAS28 was also evaluated
after patients had participated in the LTE study for 3 months.
The DAS28 clinical efficacy evaluation was used to assess corre-
lations with the biomarker changes observed on Day 28 of the
A3921073 study. Additional clinical assessment was performed
at 4 months from A3921073 baseline in the A3921024 study.
Synovial biopsies
Synovial tissue was acquired arthroscopically using automated
motorised shaver technology. Pools of >10 tissue fragments
each were aliquoted for histology, mRNA or protein analysis.
For synovial immunohistochemistry, Optimal Cutting
Temperature medium (OCT®) frozen blocks were made. Tissue
fragments were frozen in an RNA STAT-60 for mRNA measure-
ments. STAT protein analysis was performed on snap frozen
tissue fragments.
Synovial gene expression analysis
Synovial RNA was extracted from pooled tissue fragments and
cDNA was synthesised.21 Quantitative PCR (qPCR) was per-
formed using predeveloped reagents (Applied Biosystems, Foster
City, California, USA). Results were compared with a reference
standard curve composed and normalised for glyceraldehyde
3-phosphate dehydrogenase.22 Post-treatment levels were
expressed as the percentage of the pretreatment geometric mean
with 95% confidence intervals from log-transformed data. The
primary mRNA analysis included a limited number paired ana-
lytes evaluating inflammatory mediators, that is, cytokines
(IL-1ß, TNF, IL-6), MMPs (MMP-1 and -3), IFN-regulated gene
(ISG15) and chemokines (CCL2, CXCL10, CXCL13).
Synovial and serum ELISAs
Serum analytes were evaluated by enzyme-linked immunosorb-
ent assay (ELISA) according to the manufacturer’s instructions.
Synovial tissue extracts for phosphorylated STAT were assayed
by ELISA.
Synovial immunohistochemistry
DAKO (Glostrup, Denmark) reagents were used for immunohis-
tochemistry according to the manufacturer’s instructions on
frozen sections (5 mm) fixed in acetone. Staining was quantified
by digital image analysis using a Nikon E800 microscope and
Image Pro software (AG Heinze, Lake Forest, California, USA).
Data were reported as average percentage area stained in six
fields.23 24
Statistical analysis
The clinical outcomes, both efficacy and safety, were sum-
marised descriptively based on the intent-to-treat (ITT) popula-
tion (patients who received ≥1 dose of randomised
investigational drug). No imputation was performed for missing
data. Synovial tissue and blood biomarkers were also sum-
marised descriptively based on the ITT population.
The change from baseline (Day -7) at Day 28 in each param-
eter reported from the synovial tissue biopsy was compared
between tofacitinib and placebo using an analysis of covariance
model with treatment as a factor and baseline as a covariate.
The change from baseline (Day 1 predose) at multiple postbase-
line time points of each blood biomarker was compared
between tofacitinib and placebo using a mixed-effects model
with treatment, visit and treatment-by-visit interaction as
fixed-effect factors, and baseline as a covariate. Correlation
among repeated measurements at different visits on the same
patient was modelled by including a common random effect in
the aforementioned model. The multiple measurements on Day
1 were analysed separately from the multiple predose measure-
ments taken on Days 10, 28, 29 and 35. No adjustments were
made for multiple comparisons.
In addition, post hoc analyses were performed to: compute
the percentage change, and associated t test-based p value, for
within-treatment-group change from baseline; compute the cor-
relation coefficient between the change in each biomarker from
baseline (Day -7) to Day 28; and the change in DAS28 from
Day 1 in the 28-day clinical study to Month 3 in the LTE study
and its associated p value based on Fisher’s transformation.
RESULTS
Patients
A total of 15 patients were randomised to tofacitinib 10 mg
twice daily plus methotrexate and 14 patients were randomised
to placebo plus methotrexate. All randomised patients (N=29)
were treated, completed the study and were analysed for efficacy
and safety. There were no discontinuations from this study. All
patients enrolled in the LTE study.
Patient demographic and baseline characteristics are shown in
online supplementary table S1. The majority of patients were
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women (26/29) and Caucasian (23/29). The mean age of all
patients was 53.3 years (range 27–77 years). The mean disease
duration was 12.2 and 5.5 years in the tofacitinib and placebo
groups, respectively. Patients in the tofacitinib group had greater
disease severity in each of the ACR criteria components (mean
scores), although the DAS28 was only slightly higher in the
tofacitinib group.
Clinical responses at Day 28 and Month 4
Tofacitinib 10 mg twice daily led to decreases in DAS28 score
compared with placebo on Day 28. Mean DAS28 scores
decreased from baseline (6.55) to Day 28 (4.90) for patients
receiving tofacitinib 10 mg twice daily compared with smaller
decreases (6.03–6.32) in the placebo group (see table 1A for
summary). After a total of 4 months’ treatment (28 days in
study 1073 and 3 months in LTE study), the tofacitinib group
had a mean DAS28 of 4.77 and the placebo group 4.72 (see
table 1B for summary of ACR and European League Against
Rheumatism responses). DAS28 on Day 28 and 4 months were
used for subsequent correlations between synovial analytes and
clinical response.
Safety
The safety experience was similar to previous tofacitinib studies.
No serious adverse events were observed (see online
supplementary table S2 for a summary of results). Three
patients in the tofacitinib group and two patients in the placebo
group had mild to moderate anaemia, and one patient receiving
placebo had potentially life-threatening anaemia. No patient
had neutrophil values of clinical concern.25
Effect of tofacitinib on synovial inflammation after 28 days
Changes in synovial cellular composition were measured by
immunohistochemistry on baseline and Day 28 biopsies. No sig-
nificant changes in CD3+ T cells, CD20+ B cells or CD68+
sublining macrophages were detected in tofacitinib or placebo
groups (table 2 and figure 1).
Effect of tofacitinib on synovial gene expression
after 28 days
qPCR was performed on biopsies taken at baseline and Day 28
and changes in gene expression were evaluated. Key genes
implicated in the pathogenesis of RA were significantly
decreased in the tofacitinib group, including MMP-1, MMP-3,
chemokine (C-X-C motif ) ligand (CXCL)13, CXCL10 and che-
mokine (C-C motif) ligand (CCL)2 (figure 2). IL-6, ISG15 and
TNF mRNA were not significantly changed on Day 28. No sig-
nificant changes in gene expression were observed in the
placebo-treated group.
Change in synovial pSTAT levels and clinical response
to tofacitinib
Clinical outcome data from the open-label LTE study on Month
3 was applied only to the tofacitinib group (13 patients received
10 mg twice daily and one patient received 5 mg twice daily in
the LTE study), since the placebo group also received tofacitinib
after LTE enrolment. The strongest correlation was an associ-
ation between decreased synovial pSTAT levels after 1 month of
tofacitinib treatment in the placebo-controlled study and clinical
improvement after a total of 4 months including the LTE.
STAT1 and STAT3 activation, as determined by phosphorylation
of the transcription factors, were highly correlated with the
change in DAS28 (r=0.755, p=0.0018 and r=0.874,
p<0.0001, respectively) (figure 3). No changes in the levels of
other biomarkers, including MMP-1, MMP-3, CXCL10 or
CXCL2 correlated with clinical improvement.
Relationship between baseline synovial biomarkers
and clinical response
We then evaluated whether baseline mRNA biomarker expres-
sion and STAT phosphorylation predict clinical response
(DAS28) after 4 months’ treatment with tofacitinib. Only
MMP-3 was statistically significant, with a higher pretreatment
value correlating with improved response (p=0.0360;
r=0.580).
Serum CXCL10 as a pharmacodynamic biomarker
of tofacitinib activity
Serum chemokines were also evaluated at various times during
the 28-day study. The most prominent finding was a rapid
decrease in the IFN-regulated gene CXCL10, which was
observed as early as 4 h after the first tofacitinib dose and which
remained low throughout the treatment period (figure 4). One
Table 1 Clinical efficacy, as measured by EULAR response rate
and ACR response rate, at (A) Day 28 and (B) after a total of
4 months’ treatment
(A)
Tofacitinib
10 mg BID Placebo
EULAR response, n/N (%)
Good 1/14 (7.1%)* 0/14
Moderate 10/14 (71.4%) 1/14 (7.1%)
None 3/14 (21.4%) 13/14 (92.9%)
ACR response, n/N (%)
ACR20 9/15 (60.0%) 0/14 (0)
ACR50 6/15 (40.0%) 0/14 (0)
ACR70 1/15 (6.7%) 0/14 (0)
*One patient did not have ESR for calculation of EULAR responses.
Table 2 IHC of synovial biopsy tissue
% Change in IHC score
Day -7 to Day 28
p Value
(tofacitinib
vs placebo)
Tofacitinib
10 mg BID, % (N)
Placebo,
% (N)
CD3+ T cell 1.59 (10) 0.02 (8) 0.5811
CD20+ B cell 2.08 (10) -1.68 (10) 0.1748
CD68+ sublining
macrophage
1.77 (12) 0.71 (11) 0.8605
See Methods, Synovial immunohistochemistry for description of image analysis methods.
BID, twice daily; IHC, immunohistochemistry; N, number of samples that were evaluated.
(B)
Tofacitinib
10 mg BID
EULAR response, n/N (%)
Good 2/13 (15.4%)
Moderate 9/13 (69.2%)
None 2/13 (15.4%)
ACR response, n/N (%)
ACR20 6/13 (46.2%)
ACR50 5/13 (38.5%)
ACR70 2/13 (15.4%)
ACR, American College of Rheumatology; BID, twice daily; ESR, erythrocyte
sedimentation rate; EULAR, European League Against Rheumatism.
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week after discontinuation of tofacitinib, CXCL10 levels
returned to baseline. Both serum CXCL10 and synovial mRNA
expression were reduced overall by tofacitinib activity; however,
the levels at baseline or changes induced by tofacitinib did not
correlate between serum and synovium (p>0.05). Furthermore,
neither measure correlated with clinical response at 4 months
(p>0.05).
DISCUSSION
We tested the hypothesis that tofacitinib targets cytokine signal-
ling implicated in RA within the synovium. Tofacitinib reduced
the synovial expression of MMPs and IFN-regulated genes in
rheumatoid synovium. Analyses of the open-label LTE study
3-month efficacy data demonstrated a clear correlation between
inhibition of synovial STAT1 and STAT3 activation after
1 month of therapy during the synovial biopsy portion of the
study and the magnitude of clinical improvement assessed in the
LTE (total 4 months of treatment with tofacitinib). These data
suggest that JAK1-mediated signalling of IFNs and IL-6 plays a
key role in the synovial response to JAK blockade.
Since cytokine inhibitors decrease disease activity in RA,
blocking kinases in the signal transduction cascade could poten-
tially have the same benefit. Targeting JAK proteins has met
with success in clinical trials, and several JAK inhibitors have
demonstrated efficacy in RA, similar to biological agents, in par-
ticular, tofacitinib.11 In addition to tofacitinib, these include
several other JAK inhibitors with varying specificities for JAK
isoforms, including baricitinib, VX509 and GLPG0634.11
The four JAK proteins ( JAK1, 2, 3 and Tyk2) form a family of
signalling molecules that associate with cytokine receptors.9 10
Combinations of JAK1 and/or JAK2 can transduce signals when
members of the IL-6 family ligate their receptors, thereby activating
their downstream targets, for example, STAT1 and STAT3.9 10
JAK1/JAK3 combinations facilitate signalling for cytokines that use
the common gamma-chain receptor, particularly Tcell cytokines.9 10
IFNs use several JAK/STAT combinations, but JAK1/Tyk2 and
STAT1 are particularly important.9 10 Although the TNF receptor
does not directly signal through JAKs, synoviocyte activation by
TNF stimulation can be affected by JAK-dependent pathways.26
The relative contribution of specific JAK isoforms remains
uncertain. In the present study, synovial biopsies were per-
formed pretreatment and after 4 weeks of study treatment and
correlated with clinical outcome. The selection of week 4 for
the second biopsy and 4 months total exposure for clinical
evaluation was based on our goal of identifying leading synovial
biomarkers of clinical response rather than concomitant
response. The 4-month time point allows comparison with the
full clinical response.26
Unexpected issues in the current study were differences in
disease duration and baseline severity between the two treat-
ment groups, which were due to chance. The imbalance high-
lights the relatively small size of the study and the resulting
limitations in statistical power which restricts the ability to
perform stratification of subjects based on synovial architecture
or clinical characteristics at baseline. This imbalance could con-
tribute to differences when comparing synovial analytes in the
placebo group with the tofacitinib group. Thus, relative changes
of biomarkers within the groups were considered especially
important.
Some therapeutic agents, such as TNF inhibitors and
intra-articular steroids, cause a rapid and dramatic decrease in
synovial inflammation;27 others show modest effects (methotrex-
ate). Abatacept and rituximab cause minimal or no effect on the
total cellular inflammation score at early time points.21 28 29 This
is also the case with tofacitinib because cell infiltration is not sig-
nificantly changed after 4 weeks of therapy. Individual cell
lineages can be depleted with other agents, most notably B cells
with rituximab; no significant effects of JAK inhibition on macro-
phage, B cell or Tcell infiltration were observed at month 1.
Figure 1 Absence of significant changes in CD68+ sublining macrophages. Representative synovial tissue samples were analysed by
immunohistochemistry for CD68+ sublining macrophages at Day -7 (left) and Day 28 after tofacitinib treatment (right) (original magnification ×200).
Figure 2 Tofacitinib significantly reduced synovial chemokine and
matrix metalloproteinase expression. BID, twice daily; CI, confidence
interval; CCL, chemokine (C-C motif ) ligand; CXCL, chemokine
(C-X-C motif ) ligand; IL, interleukin; IP-10, interferon gamma-induced
protein 10; MCP-1, monocyte chemotactic protein-1; MMP, matrix
metalloproteinase.
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The synovial biomarker study was notable for
tofacitinib-induced decreases in expression of genes implicated
in RA, including MMPs and chemokines. No significant effects
were observed for any biomarker in the placebo group.
Pretreatment levels of synovial biomarkers did not predict
which patients would respond to tofacitinib and response was
not associated with high or low relative synovial STAT phos-
phorylation at baseline.
Blood biomarkers were also assessed. A rapid and sustained
decrease in CXCL10, which was also decreased in synovial
tissue, was observed. Although CXCL10 serum protein and syn-
ovial mRNA levels were reduced by tofacitinib, changes in
expression did not correlate to each other. CXCL10 is especially
interesting because an anti-CXCL10 antibody has demonstrated
some clinical benefit in RA.30 Therefore, the effect on this par-
ticular chemokine could be useful as a pharmacodynamic
marker of tofacitinib activity. The role of CXCL10 as a type I
IFN-induced and STAT-regulated chemokine suggests a role for
IFN-mediated mechanisms. The ultimate utility of serum
CXCL10 measurements could best be resolved in larger clinical
studies.
Perhaps the most important finding of our study was the cor-
relation between suppression of STAT activation, evidenced by
STAT phosphorylation, and later clinical improvement. The pre-
treatment levels of pSTAT did not predict response to therapy
possibly because the tofacitinib-treated group had greater
disease severity. However, the declines in synovial pSTAT1 and
pSTAT3 after 1 month were highly correlated with the degree
of clinical response, as determined by change in DAS28.
The correlation of change in pSTATwith clinical response, taken
with the lack of change in synovial cellularity, suggests that
the effect is transcription dependent. Further evaluations of
tofacitinib inadequate responders, particularly those with high
pSTATs at baseline, could provide insights into other roles of
JAK-STAT signalling in RA.31
The biomarker data provide some clues to the mechanism of
action of tofacitinib. Interfering with the JAK1-STAT3 pathway
suggests that blocking IL-6 signalling contributes to the mechan-
ism of action. However, the effects on pSTAT1 and
IFN-regulated genes, such as CXCL10 production, suggest that
the mechanism also involves blockade of IFN signal transduction.
The potential importance of IFN blockade in clinical efficacy is
supported by our recent observation that TNF-mediated synovio-
cyte activation is mediated by IFN production and JAK/
STAT-induced expression of chemokines such as CXCL10.26
Therefore, tofacitinib can block IL-6 signalling directly and TNF
function through an indirect mechanism. The contribution of
individual synovial cell types to tofacitinib therapeutic sensitivity
is still unknown and requires a larger study to evaluate the indi-
vidual roles of B cells, Tcells, macrophages and synoviocytes.
In conclusion, the data suggest that tofacitinib regulates
JAK-mediated events in the rheumatoid synovium. Rather than
blocking a single cytokine, tofacitinib modulates IL-6 and IFN
signalling. JAK1 inhibition, with early suppression of STAT1
and STAT3, correlates well with longer-term clinical benefit.
Figure 3 Tofacitinib-induced synovial change in pSTAT3 and pSTAT1 at Day 28 predicts clinical response at 4 months. *Biomarker data change
from baseline (Day -7) to Day 28. **DAS28-4(ESR) change from Day 1 to Month 4. DAS, disease activity score; ESR, erythrocyte sedimentation rate;
pSTAT, phosphorylated signal transducer and activator of transcription; r, correlation coefficient; STAT, signal transducer and activator of
transcription.
Figure 4 CXCL10 plasma levels in tofacitinib or placebo-treated
patients with rheumatoid arthritis. *p<0.05, **p<0.005 change from
Day 1 pre-dose relative to placebo. BID, twice daily; CXCL10,
chemokine (C-X-C motif ) ligand 10; LS, least squares; RA, rheumatoid
arthritis; SE, standard error; LS means were calculated using two
models; one for the measurements on Day 1, and one for the
remaining measurements.
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Finally, the effects of tofacitinib on blood chemokines such as
CXCL10 suggest that biomarkers might be used to either
predict or evaluate therapeutic response.
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